A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
Status:
Terminated
Trial end date:
2016-01-30
Target enrollment:
Participant gender:
Summary
To compare the efficacy of oral brincidofovir (BCV) to valganciclovir (vGCV) for the
prevention of cytomegalovirus (CMV) disease in kidney transplant allograft recipients who are
CMV seronegative pretransplant and received a kidney from a CMV seropositive donor